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A B S T R A C T
Purpose: The aim of this study is to present the treatment modalities and associated side effects in a Polish
nation-wide ANCA-associated vasculitides (AAV) patients’ cohort.
Materials and methods: Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included
in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on
the treatment modalities.
Results: There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with
polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic
granulomatosis with polyangiitis (EGPA; 16.3%). The mean age at the date of diagnosis was 50.4 (± 15.7) years
and the median observational period amounted to 4.0 (2.0–8.0) years.
Glucocorticosteroids (GCs) were the medicaments most frequently used for remission induction (593/622;
95.3%), followed by cyclophosphamide (487/622; 78.3%), rituximab (44/622; 7.1%), and methotrexate (39/
622; 6.3%). GCs were also most frequently administered for maintenance therapy (499/592; 84.3%), followed
by azathioprine (224/592; 37.8%), methotrexate (136/592; 23.0%) and mycophenolate mofetil (99/592;
16.7%). The median cumulative doses of cyclophosphamide and rituximab equalled 7.99 g (4.18–14.0) and
2000 mg (1500–2800), respectively. The most commonly observed adverse events included: infections - 214/
551 cases (38.8%), which were associated with the time of observation (OR = 1.05; 95% CI 1.01–1.10), the use
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of GCs intravenous pulses (OR = 2.76; 95% CI 1.68–4.54) and need for haemodialysis (OR = 1.73; 95% CI
1.10–2.71).
Conclusions: Polish patients with AAV were predominantly treated according to appropriate guidelines. The
most frequent adverse events were typical for usually administered immunosuppressive treatment.
1. Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculi-
tides (AAV) are a group of rare, autoimmune diseases, affecting pre-
dominantly small vessels. According to the 2012 Revised International
Chapel Hill Consensus Conference Nomenclature of Vasculitides, the
group of AAV consists of three distinct entities, namely, granulomatosis
with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosino-
philic granulomatosis with polyangiitis (EGPA) [1]. The annual in-
cidence of these diseases is estimated to be 4.9–10.2 per million for
GPA, 2.7–11.6 per million for MPA and 0.5–4.2 per million for EGPA
[2]. Since glucocorticosteroids and the other immunosuppressive drugs
were introduced for the management of AAV, the outcomes for the
sufferers have significantly improved and these disorders have changed
their status from rapidly progressive and inevitably fatal conditions to
chronic, relapsing diseases, if early diagnosed and properly treated.
Despite this undeniable progress, the optimal treatment regimens are
still being discussed and revised, with relevant difficulties related to the
rarity of the diseases and scarcity of the large clinical trials. Moreover,
due to generally better prognosis, the short and long-term complica-
tions of the treatment have become an important factor influencing
mortality and morbidity. For these reasons, search for optimal treat-
ment regimens, tailored for distinct subsets of AAV, and careful mon-
itoring of possible side effects are warranted.
1.1. POLVAS
Due to the rarity of AAV, it is impossible for a single centre to design
and pursue prospective, randomized, clinical trials regarding manage-
ment. Therefore, multi-center databases – called Rare Diseases
Registries (RDRs) - are recommended by the European Union
Committee of Experts on Rare Diseases (EUCERD) [3].In 2014, the
Consortium of the Polish Vasculitis Registry (POLVAS) was established
[4], consisting of both retrospective and prospective branches of the
registry. The aim of this study is to present the treatment modalities and
associated side effects among the patients of Polish population with
AAV registered in the retrospective part of POLVAS database.
2. Material and methods
2.1. Methods
In the retrospective part of POLVAS database, 625 cases of AAV
were included, encompassing patients diagnosed with AAV from 1990
to 2016, who stayed under the care of POLVAS affiliated centers. The
POLVAS registry structure was described elsewhere [4,5]. The medical
history of the participants was analysed retrospectively and the data
regarding treatment protocols, adverse effects and complications were
collected using electronic questionnaires. All cases of AAV available in
the documentation gathered in POLVAS affiliated centers were included
into retrospective part of POLVAS.
The vasculitides diagnoses were made according to the American
College of Rheumatology (ACR) classification and 2012 Revised
International Chapel Hill Consensus criteria [1,6].
Additionally, AAV patients were subdivided into 3 subgroups ac-
cording to the time when definite diagnosis was established, i.e. 1)
before 2004, 2) between 2004 and 2010, and 3) after 2010). The di-
vision was based on the time of publishing the results of breakthrough
researches - CYCAZAREM in 2003, and RAVE and RITUXIVAS both in
2010 [7–9] – which significantly influenced treatment regimens in
AAV.
2.2. Ethical issues
The study was carried out in accordance with The Code of Ethics of
the World Medical Association (1964 Declaration of Helsinki). The
study protocol was approved by Jagiellonian University Bioethics
Committee (Poland), approval No. 122.6120.25.2016. All POLVAS sites
acquired local ethics committee approval before starting the recruit-
ment.
2.3. Statistical analysis
Standard descriptive statistics were used. Normal distribution of
variables was checked by Shapiro-Wilk test, and Levene's test served to
assess homogeneity of variances. To compare the studied groups χ2 test
(with Yates correction if needed) was used. Univariate ANOVA with
post-hoc test was performed for comparisons of normally distributed
variables and Kruskal-Wallis test with pairwise comparisons or Mann-
Whitney U test were carried out for comparisons of non-normally dis-
tributed variables. Binary logistic regression was used for assessment of
the odds ratios of distinct variables. The p-value<0.05 was assumed as
statistically significant, modified with Bonferroni correction when
multiple comparisons were performed. Calculations were performed
with StatSoft Statistica 13 software (StatSoft®, Tulsa, OK, USA) and
SPSS Statistics (IBM®, USA).
Table 1
Basic description of the group.
All GPA MPA EGPA p-valuea
No. of cases (N) 625 417 (66.7%) 106 (17.0%) 102 (16.3%) –
Men 298 (47.7%) 210 (50.4%) 54 (50.9%) 34 (33.3%) 0.1009
Mean age (years) 50.4 ± 15.7 49.0 ± 15.3 61.5 ± 13.8 44.8 ± 14.4 <0.0001
Median observation (years) 4.0 (2.0–8.0) 5.0 (2.0–8.0) 2.0 (1.0–4.0) 5.5 (3.0–10.0) 0.0206
Deaths 56 (8.96%) 42 (10.07%) 13 (12.26%) 1 (0.98%) GPA vs MPA GPA vs EGPA MPA vs EGPA
0.5112 0.0053 0.0030
Cases with at least one relapseb 340 (54.9%) 243 (58.8%) 27 (25.5%) 70 (70.0%) GPA vs MPA GPA vs EGPA MPA vs EGPA
<0.0001 0.0400 <0.0001
Statistically significant p-values are bolded.
a P-value is evaluated for the group of all cases. χ2 and Kruskal-Wallis tests were used (assumed level of significance = 0.05).
b There were 6 cases with no available data in this analysis – 4 cases of GPA and 2 cases of EGPA.
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3. Results
3.1. Group description
Six hundred and twenty-five patients were qualified to this study
(all patients included in the retrospective POLVAS database). Among
them, there were 417 cases of GPA (66.7%), 106 cases of MPA (17.0%)
and 102 cases of EGPA (16.3%). The median time of observation (de-
fined as the difference between the date of inclusion to the database and
the date of establishment of the diagnosis) equalled 4.0 (2.0–8.0) years
with the shortest observation in MPA (2.0; 1.0–4.0 years). Basic de-
mographic characteristics are presented in Table 1. There were 469
ANCA positive patients, 62 ANCA negative patients (mostly in EGPA
group) and 94 had unknown ANCA status. Detailed immunological
profile of included subjects is presented in the Supplementary Table s1.
3.2. Treatment - remission induction
Remission induction treatment was defined as the therapy used ei-
ther until remission achievement or during the first six months of
treatment, if the remission was not achieved. Glucocorticosteroids
(GCs) were the drugs most frequently used for remission induction
therapy. There was no statistical difference in GCs use between AAV
groups. GCs pulses, defined as administering 500 mg or more methyl-
prednisolone (or other GCs in equivalent dose) in a single intravenous
(i.v.) infusion were used in 378 cases (378/513; 73.7%). Patients with
GPA, as well as those with MPA were administered GCs pulses more
frequently than patients diagnosed with EGPA (283/368, 76.9% vs. 19/
48, 39.6%; p < 0.0001 and 76/97, 78.4% vs. 19/48, 39.6%;
p < 0.0001, respectively).
The second immunosuppressive agent most frequently used for re-
mission induction was cyclophosphamide (487 cases; 78.3%), followed
by rituximab (58 cases; 9.3%). Cyclophosphamide was used sig-
nificantly more often in GPA and MPA than in EGPA (355/414, 85.7%
vs. 44/102, 43.1%; p < 0.0001 and 88/106, 83.0% vs. 44/102, 43.1%;
p < 0.0001, respectively). Rituximab was used more frequently in
GPA than in MPA (53/414, 12.8% vs. 5/106, 4.7%; p < 0.02). None of
the patients with EGPA received rituximab for remission induction
treatment.
On the contrary, the use of methotrexate, as well as azathioprine
was significantly more frequent in EGPA comparing to GPA and to MPA
(methotrexate: 16/102, 15.7% vs. 22/414, 5.3%; p = 0.0003 and 16/
102, 15.7% vs. 1/106, 0.9%; p = 0.0003, respectively; azathioprine:
14/102, 13.7% vs. 14/414, 3.4%; p < 0.0001 and 14/102, 13.7% vs.
2/106, 1.9%; p = 0.0033, respectively). More detailed information is
presented in Table 2.
3.3. Renal replacement therapy
Haemodialysis was required in 134 (21.9%) of all AAV cases during
the analysed period. Ninety one patients (14.8%) required haemodia-
lysis permanently while 43 (7.0%) were hemodialyzed temporarily
during the course of the disease. None of EGPA patients needed renal
replacement therapy. MPA patients predominated among patients re-
quiring dialysis (47/106, 44.3% vs. 87/405, 21.5%; p < 0.001). The
details are presented in Table 3. Among the patients who needed renal
replacement therapy, the only significant difference between tem-
porarily and permanently hemodialyzed was the age (p = 0.002;
medians - 60 and 54 years, respectively.) The details are presented in
the Supplementary Table s2.
3.4. Treatment – maintenance therapy
Maintenance treatment was defined as the therapy after remission
achievement or after the first 6 months of treatment, if the remission
was not achieved. GCs were used for maintenance therapy in 499 cases
(84.3%). In most cases with available data, GCs were used for the whole
time of observation (median = 100.0% (70.0–100.0)).Other im-
munosuppressive drugs used frequently for maintenance therapy were:
azathioprine (224 cases; 37.8%), methotrexate (136 cases; 23.0%),
mycophenolate mofetil (99 cases; 16.7%) and cyclophosphamide (70
cases; 11.8%). No maintenance treatment was used in 36 cases (6.1%).
Azathioprine was administered more frequently to GPA patients than to
MPA (162/402, 40.3% vs. 23/103, 22.3%; p = 0.0007) and also sig-
nificantly more frequently in EGPA as compared to MPA (39/87, 44.8%
vs. 23/103, 22.3%; p = 0.0010). Similarly, methotrexate was used
more frequently in GPA comparing with MPA (104/402, 25.9% vs. 8/
103, 7.8%; p = 0.0001) and again administered more frequently in
EGPA as compared with MPA (24/87, 27.6% vs. 8/103, 7.8%;
p = 0.0003). The details are presented in Table 4.
Table 2
Treatment use for remission induction.
All GPA MPA EGPA GPA/MPA GPA/EGPA MPA/EGPA
GCs use (all forms of administration) # 593 (95.3%) 388 (93.7%) 104 (98.1%) 101 (99.0%) 0.1219 0.0568 0.9732
GCs only orally 123 (19.8%) 75 (18.1%) 15 (14.2%) 33 (32.4%) 0.3356 0.0015 0.0018
GCs only intravenously 187 (30.1%) 124 (30.0%) 60 (56.6%) 3 (2.9%) <0.0001 <0.0001 <0.0001
GCs both orally and intravenously 281 (45.2%) 187 (45.2%) 29 (27.4%) 65 (63.7%) 0.0009 0.0008 <0.0001
GCs without any other immunosuppressive drug 78 (12.5%) 27 (6.5%) 15 (14.2%) 36 (35.3%) 0.0101 <0.0001 0.0004
GCs pulses used (at least 1) 378† (73.7%) 283 ‡ (76.9%) 76 § (78.4%) 19 (39.6%) 0.5068 <0.0001 <0.0001
No GCs 29 (4.7%) 26 (6.3%) 2 (1.9%) 1 (1.0%) 0.1219 0.0568 0.9732
CYC # 487 (78.3%) 355 (85.7%) 88 (83.0%) 44 (43.1%) 0.4801 <0.0001 <0.0001
RTX # 58 (9.3%) 53 (12.8%) 5 (4.7%) 0 (0.0%) 0.0183 – -
MTX # 39 (6.3%) 22 (5.3%) 1 (0.9%) 16 (15.7%) 0.0914 0.0003 0.0003
AZA # 30 (4.8%) 14 (3.4%) 2 (1.9%) 14 (13.7%) 0.6312 <0.0001 0.0033
MMF # 5 (0.8%) 3 (0.7%) 0 (0.0%) 2 (2.0%) – 0.5637 -
IVIG # 31 (5.0%) 26 (6.3%) 3 (2.8%) 2 (2.0%) 0.2527 0.1386 0.9653
Plasmaphereses+ 72 (11.7%) 56 (13.8%) 16 (15.1%) 0 (0.0%) 0.7385 – -
# No data in 3 cases of GPA; † 513 cases available for GCs pulses analysis; ‡ 368 cases available for GCs pulses analysis; § 97 cases available for GCs pulses analysis; ¶
48 cases available for GCs pulses analysis.
+No data in 12 cases of GPA.
Additionally, 2 cases of GCs use in unknown form, 2 cases of cyclosporine use, 1 case of sulfasalazine use and 1 case of chloroquine use in induction remission.
Assumed statistical significance level of χ2 test (with Yates correction if needed) = 0.05, adjusted with Bonferroni correction if multiple comparisons per-
formed = 0.017.
Statistically significant p-values are bolded.
Abbreviations: GCs = glucocorticoids; CYC = cyclophosphamide; RTX = rituximab; MTX = methotrexate; AZA = azathioprine; MMF = mycophenolate mofetil;
IVIG = intravenous immunoglobulins.
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3.5. Cumulative immunosuppressive drug doses
The median cumulative dose of cyclophosphamide equalled 7.99 g
(4.18–14.0). The highest amount of cyclophosphamide was adminis-
tered to GPA patients (9.0 g; 5.3–16.0). The median cumulative dose of
cyclophosphamide adjusted for a year of observation equalled 2.65 g/
year with no statistically significant differences between the subgroups
(GPA, MPA, EGPA). There were 46 cases (46/493; 9.33%), in which the
cumulative dose of 25 g was exceeded, mainly diagnosed with GPA. The
median cumulative dose of rituximab equalled 2000 mg (1500–2800).
More details are available in the Supplementary Table s3 and
Supplementary Table s4.
3.6. Differences in AAV patients diagnosed in different time periods
The analysis of AAV group, based on the time of diagnosis was
performed. The lowest use of cyclophosphamide as the maintenance
treatment was in the group diagnosed after 2010 (20//351; 5.70%),
comparing to the group with diagnosis made before 2004 (18/69;
26.09%; p < 0.0001) and group diagnosed between 2004 and 2010
(31/195; 15.90%; p = 0.0001). The use of azathioprine and metho-
trexate was also lower in patients diagnosed in the most recent period
than in the earlier periods (p = 0.0004 and 0.0115 for azathioprine use
and methotrexate use, respectively). The details are presented in Fig. 1
and in the Supplementary Table s5. The rate of adverse events as re-
lated to the time period when the AAV diagnosis was established is
displayed in Fig. 1.
3.7. Adverse events
Adverse events occurred in 377 of AAV patients with infections
being the most common. The definitions of adverse events were based
mainly on clinical assessment (more detailed information with full list
of side effects is provided in the Supplementary Table s6. All mentioned
cases of infections in the medical documentation were considered as
relevant. Patients who developed infections were characterized by the
longer average observation time (median 4.75 years vs. 2.75 years;
p = 0.034; OR = 1.05; 95% CI 1.00–1.10). Also, they more often re-
ceived GCs pulses (at least one pulse vs. no pulses; 75.2% vs. 61.7%;
p < 0.001; OR = 2.83; 95% CI 1.73–4.64) and more frequently
needed haemodialysis (29.38% vs. 18.37%; p = 0.018; OR = 1.725;
95% CI 1.10–2.71). Cumulative cyclophosphamide dose was not asso-
ciated with occurrence of infections (p = 0.092). The detailed data are
presented in Table 5.
3.8. Relapses and mortality
The highest proportion of patients who developed relapses was in
the EGPA subgroup. In the analysis, regarding cumulative number of
relapses in our AAV population, the association with infections was
found (p = 0.0002; results obtained using linear regression model). No
factors were revealed to be associated with the occurrence of relapses
which required hospitalisation. More information concerning relapses
is available in Table 1.
There were 56 deaths among all patients with AAV (8.96%). The
mortality rate was similar in GPA and MPA groups (10.07% and
12.26%, respectively; p = 0.5112), whereas only 1 patient diagnosed
with EGPA died (0.98%). Treatment related factors associated with
death were: need for haemodialysis (p < 0.0001) and steroid pulse use
(p = 0.0425). The more detailed description of mortality among the
cases gathered in the POLVAS retrospective database is presented in
another publication [10].
Table 3
Renal replacement therapy.
All GPA MPA EGPA GPA/MPA * (p-value)
No. of cases (N) 613 405 106 102 –
Haemodialysis (totally) 134 (21.9%) 87 (21.5%) 47 (44.3%) 0 (0.0%) <0.0001
Haemodialysis temporarily 43 (7.0%) 32 (7.9%) 11 (10.4%) 0 (0.0%) 0.4136
Haemodialysis permanently/End stage renal disease 91 (14.8%) 55 (13.6%) 36 (34.0%) 0 (0.0%) <0.0001
Assumed statistical significance level of χ2 test (with Yates correction if needed) = 0.05.
Comparison was performed only between GPA and MPA group, as there was no case of EGPA who needed renal replacement therapy.
Statistically significant p-values are bolded.
Table 4
Immunosuppressive drugs used among those who received maintenance therapy.
All GPA MPA EGPA GPA/MPA (p-value) GPA/EGPA (p-value) MPA/EGPA (p-value)
No. of cases (N) 592 402 103 87 – – –
GCs 499 (84.3%) 333 (82.8%) 86 (83.5%) 80 (92.0%) 0.8738 0.0333 0.0804
AZA 224 (37.8%) 162 (40.3%) 23 (22.3%) 39 (44.8%) 0.0007 0.4363 0.0010
MTX 136 (23.0%) 104 (25.9%) 8 (7.8%) 24 (27.6%) 0.0001 0.7414 0.0003
MMF 99 (16.7%) 74 (18.4%) 16 (15.5%) 9 (10.3%) 0.4965 0.0693 0.2918
CYC 70 (11.8%) 50 (12.4%) 10 (9.7%) 10 (11.5%) 0.4450 0.8078 0.6895
CYA 23 (3.9%) 19 (4.7%) 2 (1.9%) 2 (2.3%) – – –
CLQ and HCQ 11 (1.9%) 7 (1.7%) 0 (0.0%) 4 (4.6%) – 0.1033 –
RTX 8 (1.4%) 6 (1.5%) 2 (1.9%) 0 (0.0%) – – –
LEF 2 (0.3%) 2 (0.5%) 0 (0.0%) 0 (0.0%) – – –
Other biological agents † 5 (0.8%) 3 (0.7%) 0 (0.0%) 2 (2.3%) – – –
IVIG 9 (1.5%) 8 (2.0%) 1 (1.0%) 0 (0.0%) – – –
No maintenance treatment 36 (6.1%) 28 (7.0%) 6 (5.8%) 2 (2.3%) 0.6804 – –
† Belimumab, tralokinumab, infliximab.
8 patients (5 with GPA and 3 with MPA) died < 6 months after AAV diagnosis – they were excluded from analysis pertaining maintenance therapy.
Assumed statistical significance level of χ2 test (with Yates correction if needed) = 0.05, adjusted with Bonferroni correction if multiple comparisons per-
formed = 0.017.
Statistically significant p-values are bolded.
Abbreviations: GCs = glucocorticoids; AZA = azathioprine; MTX = methotrexate; MMF = mycophenolate mofetil; CYC = cyclophosphamide;
CYA = cyclosporine; CLQ = chloroquine; HCQ = hydroxychloroquine; RTX = rituximab; LEF = leflunomide; IVIG = intravenous immunoglobulins.
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4. Discussion
Based on the POLVAS registry database, we characterised the
treatment of AAV in Poland. Demographic characteristics of described
population did not vary considerably comparing to the populations in
similar studies [11–15]. Generally, AAV therapy was consistent with
recently published guidelines [16,17]. Of note, 6.1% of patients in our
study did not receive any maintenance treatment, after exclusion of
patients who had died before starting maintenance therapy. However, it
might be a result of a short follow up in cases still being in an induction
phase of remission by the time of recording their data in the registry.
The median cumulative dose of cyclophosphamide amounted to 7.99 g,
and does not exceed suggested whole-life dose of 25 g [17]. However,
9.33% of registered population received doses greater than 25 g. Cu-
mulative doses of cyclophosphamide in our study were lower than those
reported in patients before publication of CYCAZAREM [7] and CY-
CLOPS [18,19] results and comparable to or even lower than doses
reported in later studies [11,20–23]. In the vast majority of cases GCs
were used permanently during the whole observation time, probably
due to predominance of cases with rather short observation time. Al-
ternatively, it might show the tendency to prolong maintenance therapy
with systemic GCs. Due to frequent adverse events associated with such
treatment much shorter periods of steroid therapy are now suggested in
the AAV patients [16,17,24].
There were some significant differences in the way AAV patients
were treated depending on the clinical diagnosis. GCs were frequently
the only agents used for induction of remission in EGPA patients,
consistent with former guidelines to use steroid monotherapy in less
severe cases [25,26]. However, according to newer data, concomitant
use of GCs together with an additional immunosuppressive drug is
suggested for all EGPA cases [27,28].More frequent use of methotrexate
and azathioprine, less frequent use of cyclophosphamide as well as GCs
pulses and no use of rituximab or plasmaphereses - these differences
may reflect less severe course of EGPA, comparing to the other AAV
entities. However, due to the lack of the Birmingham Vasculitis Activity
Score (BVAS) and Five Factor Score (FFS) such assumption could not be
definitely supported. Patients with MPA required haemodialysis sig-
nificantly more frequently than GPA patients. This is consistent with
other reports showing that diagnosis of MPA and anti-myeloperoxidase
antibodies (anti-MPO) positivity are associated with severe renal in-
volvement [29,30]. Cumulative dose of cyclophosphamide was higher
in GPA comparing to MPA, which may be due to the higher tendency to
relapse in anti-proteinase 3 antibodies (anti-PR3) positive cases
[31,32]. However, it might be also influenced by shorter observational
time in MPA group, as adjustment of cumulative dose of cyclopho-
sphamide for the length of observation showed similar cumulative dose
of cyclophosphamide per year of observation. We also noticed a rela-
tively high number of MPA patients treated with GCs alone for induc-
tion remission (14.2%). As the trials in which such treatment regimen
was administered showed unfavourable outcomes [33,34], and ac-
cording to the current recommendations [16], such treatment should be
abandoned.
Relatively less frequent use of rituximab in our AAV patients for
induction of remission in severe disease exacerbation was mainly due to
the lack of drug cost reimbursement program in our country at the time
of data collection. Such refunding policy started by the end of 2016
which will allow for comparison between recently recommended re-
mission induction regimens by cyclophosphamide or rituximab [16] in
a prospective arm of the POLVAS study. We also found, that renal re-
covery after the time of temporary renal replacement therapy was as-
sociated with lower age. Moreover, the results for possible correlation
of cyclophosphamide as well as plasmaphereses use with renal recovery
- the factors reported to be associated with better renal outcomes by
others - were near the threshold of statistical significance in our analysis
[35–37]. Adverse events assumed to be related to the treatment were
relatively common in the studied cohort.
Not surprisingly, the most frequently seen treatment side effects
were infections (38.8% of all cases) - similarly to the other reports
(range of infectious complications 26–39.9%) [11,15,38–40]. The fac-
tors associated with higher proportion of cases with infectious adverse
events were time of observation, GCs pulses use and need for renal
replacement therapy. The GCs pulses use might be the reflection of
more intensive treatment and the higher total dose of GCs, which was
associated with higher risk of infections in the other papers [15,41].
Three subgroups, differed by the time of diagnosis showed some in-
teresting differences. Patients diagnosed in the earlier periods received
Fig. 1. Differences between chosen factors in AAV
patients diagnosed in different periods.
Footnote: Cyclophosphamide, azathioprine, metho-
trexate, mycophenolate mofetil use during main-
tenance treatment
More detailed information is provided in the article
text and in the Supplementary Table s5.
Abbreviations: GCs = glucocorticoids; CYC = cy-
clophosphamide; RTX = rituximab; AZA = aza-
thioprine; MTX = methotrexate; MMF = mycophe-
nolate mofetil; HD = haemodialysis.
Table 5
Association of chosen factors with infections occurrence.
p Odds ratio
(exp B)
95% CI (lower
border)
95% CI (upper
border)
Cumulated CYC dose 0.092 1.012 0.998 1.026
GCs pulses use <0.001 2.759 1.677 4.536
Observation time 0.029 1.053 1.005 1.104
Haemodialysis 0.018 1.725 1.098 2.709
Binary logistic regression was used to obtain the results. Assumed level of
statistical significance = 0.05.
Statistically significant p-values are bolded.
Abbreviations: CYC = cyclophosphamide; GCs = glucocorticoids.
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higher median cumulative doses of cyclophosphamide. Also, higher
proportion of them developed infectious adverse events during follow
up – an observation already made by the other authors [15]. The pro-
portion of cases who developed infections was the lowest in the group
with diagnosis of AAV established after 2010, comparing to the groups
diagnosed in the earlier periods. It may be a reflection of changes in the
maintenance therapy over time with replacement of cyclophosphamide
by methotrexate, azathioprine or mycophenolate mofetil. On the con-
trary, it could also be associated with the shorter time of observation in
this group. Interestingly, patients with diagnosis made after 2010 had
significantly higher median dose of cyclophosphamide per year. It
could be associated with the number of patients who were during or
just after induction remission treatment in their first year of observa-
tion. A remarkable decrease in cyclophosphamide use as maintenance
therapy was seen after CYCAZAREM, than RAVE and RITUXVAS [7–9]
publications, which reflected the change in recommendations to rather
use other agents than cyclophosphamide for this phase of treatment.
Treatment-related factors associated with death were: need for hae-
modialysis which represents patients with severe renal involvement –
the known factor of poor outcome in AVV [11,42], and steroid pulses
use, which may indicate the group with more severe onset or further
course of the disease. The cumulative number of relapses was asso-
ciated with infection occurrence which could be a reflection of more
intensive treatment, required during exacerbations of disease, which in
turn may result in higher risk of infectious complications. The high
prevalence of relapses in EGPA group was probably the result of as-
suming asthma exacerbations as relapses – such statement was made in
another paper based on the data from the POLVAS population [7].
The main strength of our study is the number of cases included,
which is the largest description of treatment strategies in AAV in
Poland, and one of the largest ever reported.
On the contrary, there are also several drawbacks of this research.
First of all, the data were collected retrospectively which may have led
to some inconsistencies, errors and lacks of data. The significant
shortage of data concerns especially the area of treatment related
complications, which reaches about 50% of cases in some groups. Due
to the difficulties in obtaining all necessary data, BVAS, Vasculitis
Damage Index (VDI) and FFS indices were not assessed in the retro-
spective part of the database, so the objective judgment on cases se-
verity is limited. Because of the retrospective character of data collec-
tion, the definitions of adverse events used in the registry are generally
simplified, which may cause difficulties in detailed interpretation.
Additionally, the number of adverse events and their severity was un-
known. Relatively short time of observation may be considered as an-
other limitation when analysing the cumulative dose of drugs used. The
adjustment of the dose of immunosuppressant for a year of observation
could partially overcome this limitation. The data from retrospective
part of the database do not include also the information on the cumu-
lative doses of GCs, which does not allow to analyse the overall steroid
use. Furthermore, there are no data regarding the time to the occur-
rence of the analysed events, which makes it impossible to conduct the
time-to-event analysis. Some adverse events of immunosuppression,
such as neoplasms, may develop over longer period of time [43,44].
Therefore, their proportion might be underestimated in this study.
Prospective cohort analysis may overcome aforementioned limitations
in the future.
5. Conclusions
The treatment regimens and associated side effects among Polish
AAV population described in retrospective branch of POLVAS registry
seem to be similar to the other reports. Some differences in treatment
between specific AAV entities were found – especially EGPA patients
were treated less aggressively than those with MPA or GPA. Our ana-
lysis indicated the tendency to limit the cyclophosphamide in newer
cases, especially in maintenance therapy. Lower rituximab
administration was associated with no refunding policy to the end of
2016 year. The development of infections, which were the most fre-
quent adverse effects of treatment, was related with GCs pulses use,
time of observation and need for haemodialysis, but not with cumula-
tive dose of cyclophosphamide.
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